Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. Denlinger, C., Sym, S., Bendell, J. C., Alsina, M., Watkins, D., Chao, Y., Cubillo, A., Kunz, P. L., Sun, W., Baeksgaard, L., Chen, L., Horgan, K., Frye, S., Kudia, A. J., McDonagh, C., Czibere, A., Moyo, V. M., Chibaudel, B., Bang, Y. AMER SOC CLINICAL ONCOLOGY. 2014
View details for DOI 10.1200/jco.2014.32.15_suppl.tps4148
View details for Web of Science ID 000358613202097